Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Biosimilar Oncology Roundup for November 2023—Podcast Edition

December 3rd 2023

By Skylar Jeremias

Podcast

On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.

Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

December 2nd 2023

By Deana Ferreri, PhD

Article

A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.

The Top 5 Biosimilar Articles for the Week of November 27

December 1st 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of November 27, 2023.

Biosimilars Oncology Roundup: November 2023

November 30th 2023

By Skylar Jeremias

Article

The Center for Biosimilars® covered an abundance of oncology news during November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.

IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity

November 29th 2023

By Skylar Jeremias

Article

A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.

HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

November 28th 2023

By Skylar Jeremias

Article

Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

CVS Caremark Switches Up Biosimilar Coverage in 2024

November 27th 2023

By Denise Myshko

Article

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

Dr Chelsee Jensen Discusses Pricing Strategies for Adalimumab Biosimilars

November 26th 2023

By Skylar Jeremias

Video

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.

Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

By Deana Ferreri, PhD

Article

A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.

The Top 5 Biosimilar Articles for the Week of November 20

November 24th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of November 20, 2023.